Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Multicenter, Phase 1 Study of RP3 as a Single Agent and in Combination With PD-1 Blockade in Patients With Solid Tumors

Next Previous
Trial Profile

An Open-Label, Multicenter, Phase 1 Study of RP3 as a Single Agent and in Combination With PD-1 Blockade in Patients With Solid Tumors

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Aug 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary) ; RP 3 (Primary)
  • Indications Breast cancer; Gastrointestinal cancer; Head and neck cancer; Liver metastases; Lung cancer; Malignant melanoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Replimune

Most Recent Events

  • 07 Aug 2024 Planned End Date changed from 1 Apr 2024 to 30 Nov 2026.
  • 07 Aug 2024 Planned primary completion date changed from 1 Apr 2024 to 30 Nov 2026.
  • 21 Dec 2023 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top